A phase II study of Doxil (liposomal doxorubicin): Lack of activity in poor prognosis soft tissue sarcomas

Annals of Oncology

Volumn 9, Issue 10, 1998, Pages 1131-1133

  Garcia, A A ^a   Kempf, R A ^a   Rogers, M ^a   Muggia, F M ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Doxorubicin; Liposomal doxorubicin; Phase II; Soft tissue sarcoma

Indexed keywords

DACARBAZINE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEIOMYOSARCOMA; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN TOXICITY; SOFT TISSUE SARCOMA; STOMATITIS; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; HUMANS; MIDDLE AGED; PROGNOSIS; SARCOMA; TREATMENT OUTCOME;

EID: 0031795043     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008439013169     Document Type: Article

References (14)

1. Demetri GD, Elias AD. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Hematol Oncol Clin North Am 1995; 9: 765-85.
2. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin verus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: A randomized study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J Clin Oncol 1995; 13: 1537-45.
3. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamyein regimens for metastatic soft tissue sarcomas. J Clin Oncol 1987; 5: 840-50.
4. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis on individual data. Lancet 1997; 350: 1647-54.
5. Lasic D. Doxorubicin in sterically stabilized liposomes. Nature 1996; 380: 561-2.
6. Gabizon A, Dagan A, Goren D, Barenholz Y, Fuks Z. Liposomes as in vivo carriers of adriamycin: Reduced cardiac uptake and preserved antitumor activity in mice. Cancer Res 1982; 42: 4734-9.
7. Rahman A, Kessler A, More N et al. Liposomal protection of adriamycin-induced cardiotoxicity in mice. Cancer Res 1980; 40: 1532-37.
8. Skubitz KM. Early results of a phase II study of liposomal doxorubicin (Doxil) in refractory sarcoma. Proc Am Soc Clin Oncol 1997; 16: 509a.
9. Elson P, Chidiac T, Budd GT et al. Phase II trial of doxil in advanced soft tissue sarcomas. Proc Am Soc Clin Oncol 1998; 17: 1979a.
10. Casper ES, Schwartz GK, Sugarman A et al. Phase I trial of dose-intense liposomal encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 1997; 15: 2111-7.
11. Rydholm A. Prognostic factors in soft tissue sarcoma. Acta Orthop Scand Suppl 1997; 273: 148-55.
12. Van Glabbeke M, Van Oosterom AT, Oosterhuiss JW et al. Prognostic factors in advanced soft tissue sarcoma (sts): An over-view of 1742 patients treated with doxorubicin containing first-line regimens by the EORTC soft tissue and bone sarcoma group (STBSG). Ann Oncol 1994; 5: 171.
13. Brennan MF, Casper ES, Harrison LB. Cancer: Principles and Practice of Oncology. In De Vita VT, Hellman S, Rosenber SA (eds): Soft Tissue Sarcoma. Philadelphia: Lippinccot-Raven 1997; 1738-88.
14. Huan SK, Stauffer PR, Hong K et al. Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic efficacy of doxorubicin in sterically stabilized liposomes. Cancer Res 1994; 54: 2186-91.